Merck Q2 Results Top Estimates, But Slashes FY24 Earnings Outlook

RTTNews | hace 112

(RTTNews) - Biopharmaceutical company Merck & Co., Inc. (MRK) reported Tuesday a net profit for the second quarter compared to a loss last year, reflecting improved gross margins and a 7 percent sales growth. Both adjusted earnings per share and quarterly sales topped analysts' estimates. However, the company slashed its adjusted earnings guidance for the full-year 2024.

In pre-market activity on the NYSE, MRK shares are trading at $122.90, down $4.88 or 3.82 percent.

For the second quarter, the company reported net income attributable to the company of $5.46 billion or $2.14 per share, compared to a net loss of $5.98 billion or $2.35 per share in the prior-year quarter.

The prior-year quarter included a charge of $4.02 per share for the acquisition of Prometheus Biosciences, Inc. Excluding items, adjusted earnings for the quarter was $2.28 per share, compared to an adjusted loss of $2.06 per share in the year-ago quarter.

On average, 16 analysts polled by Thomson Reuters expected the company to report earnings of $2.15 per share for the quarter. Analysts' estimates typically exclude special items.

Worldwide total sales for the quarter increased 7 percent to $16.11 billion from $15.04 billion in the same quarter last year, driven by growth in oncology, cardiovascular and vaccines, partially offset by declines in diabetes and virology. The Street was looking for revenues of $15.84 billion for the quarter.

Excluding the Impact of Foreign Exchange, total sales increased 11 percent.

Pharmaceutical sales increased 7 percent to $14.41 billion, with KEYTRUDA sales growing 16 percent or 21 percent in constant currency, to $7.27 billion, and GARDASIL / GARDASIL 9 sales increasing 1 percent, to $2.48 billion, while JANUVIA / JANUMET sales declined 27 percent or 73 percent in constant currency, to $629 million from last year.

Animal Health sales increased 2 percent to $1.48 billion from last year, primarily driven by higher pricing in both Livestock and Companion Animal product portfolios, as well as higher demand for Livestock products.

Gross margin for the quarter improved 360 basis points to 76.8 percent, primarily due to the favorable impact of product mix

Looking ahead to fiscal 2024, Merck now projects adjusted earnings in a range of $7.94 to $8.04 per share on sales between $63.4 billion and $64.4 billion. Previously, the company expected adjusted earnings in the range of $8.53 to $8.65 per share on sales between $63.1 billion and $64.3 billion.

Analysts expect annual earnings of $8.16 per share on revenues of $64.34 billion for the year.

The outlook reflects negative impact from one-time charge of approximately $1.3 billion or $0.51 per share, for the acquisition of EyeBio.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Tags: MRK

Ligand Says Merck Receives FDA Approval For CAPVAXIVE For Adults

Ligand Pharmaceuticals Inc. (LGND) announced Tuesday that its collaborator Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, has received approval from the U.S. Food and Drug Administration (FDA) for CAPVAXIVE, previously known as V116, a 21-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in the adult population.

RTTNews | hace 154

Merck Begins Phase 3 Trial Of MK-1084 As First-Line Treatment Of Certain Metastatic NSCLC Patients

Merck & Co. Inc. (MRK), known as MSD outside of the U.S. and Canada, announced Thursday it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA for the first-line treatment of certain patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor KRAS G12C mutations and express PD-L1.

RTTNews | hace 229

Merck Says Health Canada Oks KEYTRUDA In Combination With Trastuzumab And Chemotherapy

Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, announced Monday that Health Canada has granted approval of KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumors express PD-L1 as determined by a validated test.

RTTNews | hace 281

Merck Guides FY24 EPS Above Estimates As Q4 Results Top Estimates

Biopharmaceutical company Merck reported Thursday a net loss for the fourth quarter compared to a profit last year, hurt by hefty charge, despite 6 percent sales growth. However, both adjusted earnings per share and quarterly sales topped analysts' estimates.

RTTNews | hace 292

Merck Q4 Results Top Estimates; Guides FY24 Adj. EPS Above Estimates

Biopharmaceutical company Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, reported Thursday a net loss attributable to the company for the fourth quarter of $1.23 billion or $0.48 per share, compared to net income of $3.02 billion or $1.18 per share in the prior-year quarter.

RTTNews | hace 292

Merck, Daiichi Sankyo Say FDA Grants Priority Review In U.S. For Patritumab Deruxtecan

Merck & Co. Inc. (MRK) and Japan's Daiichi Sankyo Co. Ltd. (DSKYF.PK) announced Friday that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the Biologics License Application (BLA) for patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies.

RTTNews | hace 333

Merck Says Phase 3 LEAP-001 Trial Evaluating KEYTRUDA Plus LENVIMA Did Not Meet Endpoints

Merck & Co., Inc. (MRK), known as MSD outside of the U.S. and Canada, and Japan's Eisai Co. Ltd. (ESALY.PK, ESALF.PK) announced Friday that the Phase 3 LEAP-001 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, plus LENVIMA did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) for the first-line treatment of patients with advanced or recurrent endometrial carcinoma whose disease is mismatch repair proficient (pMMR)/not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)/MSI-H.

RTTNews | hace 347

Merck Says Phase 3 KEYNOTE-A39/EV-302 Trial Meets Dual Primary Endpoints

Merck & Co Inc. (MRK), known as MSD outside of the U.S. and Canada, announced Friday positive topline results from the Phase 3 KEYNOTE-A39 trial, which was conducted in collaboration with Seagen Inc. (SGEN) and Astellas Pharma Inc. (ALPMY.PK, ALPMY).

RTTNews | hace 424

EURUSD	1.05785	GBPUSD	1.26679	AUDUSD	0.65204
USDJPY	154.408	USDCAD	1.39777	USDCHF	0.88274